Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Johns Hopkins University
With
Genentech, Inc.
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of relapsing remitting multiple sclerosis (RRMS) based on revised McDonald criteria
At least one Gd-enhancing lesions on the brain or spinal cord MRI done in the prior three months OR at least one new T2/FLAIR lesion on the brain or spinal cord MRI done in the prior three months (compared to a prior MRI performed within 18 months of the most recent MRI)
Naïve to Disease modifying therapy (DMT) or at least off these DMTs (natalizumab, fingolimod, DMF) for three months or on an injectable DMT (interferons or glatiramer acetate)
Expanded Disability Status Scale (EDSS) score at the time of screening =\<3
Negative urine or serum pregnancy test must be available for premenopausal women and for women \<12 months after the onset of menopause unless these women have undergone surgical sterilization
Women of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use one method of contraception with a failure rate of \<1% per year or a barrier method supplemented with spermicide. Contraception must continue for the duration of study treatment and for at least 24 weeks after the last dose of study treatment
You may not be if
Contraindication to treatment with an anti- cluster of differentiation antigen 20 (CD20) antibodies, including being seropositive for HBsAg
Active hepatitis B virus infection
Ever received B-cell depleting antibodies (rituximab, ocrelizumab, ofatumumab), alemtuzumab, daclizumab, mitoxantrone or hematopoietic stem-cell transplant
Pregnant or lactating women
Hypersensitivity to ocrelizumab
Treatment with steroids in the past 30 days
Clareo Health | Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis
